UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
(Mark One)
[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the fiscal year ended December 31, 2003
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from ________ to ________
Commission file number: 0-10909
PHASE III MEDICAL, INC.
(Exact name of registrant as specified in its charter)
Delaware 22-2343568
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
330 South Service Road
Suite 120
Melville, New York 11747
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (631) 574 4955
Securities registered pursuant to Section 12(b) of the Act: None.
Securities registered pursuant to Section 12(g) of the Act: Common Stock, $0.001 par value
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes [X] No [ ]
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K (ss. 229.405 of this Chapter) is not contained herein, and
will not be contained, to the best of Registrant's knowledge, in definitive
proxy or information statements incorporated by reference in Part III of this
Form 10-K or any amendment to this Form 10-K. [ ]
Indicate by check mark whether the Registrant is an accelerated filer (as
defined in Rule 12b-2 of the Act). Yes [ ] No [X]
The aggregate market value of the voting and nonvoting common equity held by
non-affiliates of the Registrant as of June 30, 2003 was approximately $ 3.1
million. (For purposes of determining this amount, only directors, executive
officers, and 10% or greater stockholders have been deemed affiliates).
On March 8, 2004, 26,926,460 shares of the Registrant's common stock, par value
$0.001 per share, were outstanding.
Documents incorporated by reference: None
This Annual Report on Form 10-K and the documents incorporated herein contain
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors which may cause the actual
results, performance or achievements of the Company, or industry results, to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. When used in this
Annual Report, statements that are not statements of current or historical fact
may be deemed to be forward-looking statements. Without limiting the foregoing,
the words "plan," "intend," "may," "will," "expect," "believe," "could,"
"anticipate," "estimate," or "continue" or similar expressions or other
variations or comparable terminology are intended to identify such
forward-looking statements. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date hereof. Except
as required by law, the Company undertakes no obligation to update any
forward-looking statements, whether as a result of new information, future
events or otherwise.
PART I
ITEM 1. BUSINESS
Phase III Medical, Inc. ("Phase III" or the "Company") (formerly known as
Corniche Group Incorporated) provides capital and guidance to companies, within
the medical sector, in exchange for revenues, royalties and other contractual
rights known as "royalty interests", that entitle it to receive a portion of
revenue from the sale of pharmaceuticals, medical devices and biotechnology
products. Previously, the Company was a provider of extended warranties and
service contracts via the Internet at warrantysuperstore.com through June 30,
2002. The business of the Company today comprises the "run off" of its sale of
extended warranties and service contracts via the Internet and the new business
opportunity it is pursuing in the medical/bio-tech sector.
HISTORY
The Company was incorporated under the laws of the State of Delaware in
September 1980 under the name Fidelity Medical Services, Inc. On July 28, 1983
the Company changed its name to Fidelity Medical, Inc. From its inception
through March 1995, the Company was engaged in the development and sale of
medical imaging products through a wholly owned subsidiary. As a result of a
reverse merger on March 2, 1995 with Corniche Distribution Limited and its
subsidiaries, the Company was engaged in the retail sale and wholesale
distribution of stationery and related office products in the United Kingdom.
Effective March 25, 1995 the Company sold its medical imaging products
subsidiary. On September 28, 1995 the Company changed its name to Corniche Group
Incorporated. In February 1996, the Company's United Kingdom operations were
placed in receivership by their creditors. Thereafter through March 1998 the
Company was inactive. On March 4, 1998, the Company entered into a Stock
Purchase Agreement with certain individuals (the "Initial Purchasers") whereby
the Initial Purchasers acquired in aggregate 765,000 shares of a newly created
Series B Convertible Redeemable Preferred Stock. Thereafter the Initial
Purchasers endeavored to establish for the Company new business operations in
the property and casualty specialty insurance and warranty/service contracts
markets. On September 30, 1998 the Company acquired all of the capital stock of
Stamford Insurance Company, Ltd. ("Stamford"). On April 30, 2001 the Company
sold Stamford and is no longer involved in property and casualty specialty
insurance.
On January 7, 2002, the Company entered into a Stock Contribution Exchange
Agreement, as amended (the "Exchange Agreement"), with StrandTek International,
Inc., a Delaware corporation ("StrandTek"), certain of StrandTek's principal
shareholders and certain non-shareholder loan holders of StrandTek (the
"StrandTek Transaction"). Consummation of the StrandTek Transaction was
conditioned upon a number of closing conditions, including the Company obtaining
financing via an equity private placement, which ultimately could not be met and
as a result, the Exchange Agreement was formally terminated by the Company and
StrandTek in June 2002. In January 2002, the Company advanced to StrandTek a
loan of $1,000,000 on an unsecured basis, which was personally guaranteed by
certain of the principal shareholders of StrandTek and a further loan of
$250,000 on February 19, 2002 on an unsecured basis. Such loans bore interest at
7% per annum and were due on July 31, 2002 following termination of the Exchange
Agreement in June 2002.
StrandTek defaulted on the payment of $1,250,000 plus accrued interest due to
the Company on July 31, 2002. As a result, on August 6, 2002, the Company filed
a complaint in the Superior Court of New Jersey entitled Corniche Group
Incorporated v StrandTek International, Inc., a Delaware corporation, StrandTek
International, Inc., a Florida corporation, David M. Veltman, William G. Buckles
Jr., Jerome Bauman and Jan Arnett. The complaint sought recovery of the
$1,250,000 loans, plus interest, costs and fees, and sought recovery against the
individual defendants pursuant to their partial guarantees. On May 9, 2003, the
Company was granted a final judgment in the amount of $1,415,622 from each
corporate defendant, in the amount of $291,405 against each individual defendant
and dismissing defendants' counterclaims.
Because the February 2002 $250,000 loan was unsecured and not guaranteed, the
Company established an allowance of $250,000 at December 31, 2002. The Company
was informed that on April 16, 2003, StrandTek made an assignment for the
benefit of its creditors, so that any collection on its judgment other than on
the personal guarantees is highly unlikely.
Between July 2003 and December 2003, guarantors Veltman, Buckles and Arnett paid
their judgments in full, with payments totaling approximately $295,000, $295,000
and $297,000 respectively. In December 2003, the Company settled with defendant
Bauman for a payment of $100,000. These payments, totaling approximately
$987,000, complete the transaction.
On July 24, 2003, the Company changed its name to Phase III Medical, Inc., which
better describes the Company's current business plan. In connection with the
change of name, the Company changed its trading symbol to "PHSM" from "CNGI".
DISCONTINUED OPERATIONS
Through April 2001 the Company operated a property and casualty reinsurance
business through its wholly owned subsidiary, Stamford Insurance Company, Ltd.
("Stamford"). Stamford is chartered under the laws of, and is licensed to
conduct business as an insurance company by, the Cayman Islands. Stamford
provided reinsurance coverage for one domestic insurance company until the
fourth quarter of 2000 when the relationship with the carrier was terminated.
Stamford was not able to obtain any additional reinsurance relationships. In
light of the inability of Stamford to write new business and difficulty in
forecasting future claims losses in the run off of its prior reinsurance
contract, on April 30, 2001, the Board of Directors of the Company approved the
sale of Stamford to Butler Financial Solutions, LLC for consideration totaling
$372,000. In the six months ended June 30, 2001, the Company recorded a loss of
approximately $479,000 on the sale of Stamford. The closing and transfer of
funds was completed on July 6, 2001.
CURRENT BUSINESS OPERATIONS
The business of the Company today comprises the "run off" of its sale of
extended warranties and service contracts via the Internet and the new business
opportunity it is pursuing as described below under the sub-heading "Recent
Developments".
WarrantySuperstore.com Internet Business
The Company's primary business focus, through June 2002, was the sale of
extended warranties and service contracts over the Internet covering automotive,
home, office, personal electronics, home appliances, computers and garden
equipment. The Company offered its products and services in the United States in
states that permit program marketers to be the obligor on service contracts.
This represented approximately 38 states for automobile service contracts and
most states for other product categories. While the Company managed most
functions relating to its extended warranty and service contracts, it did not
bear the economic risk to repair or replace products nor did it administer the
claims function. The obligation to repair or replace products rested with the
Company's appointed insurance carriers, Great American Insurance Company and
American Home Shield. Great American Insurance Company provided contractual
liability insurance covering the obligation to repair or replace products under
the Company's automobile and consumer products extended warranties and service
contracts and American Home Shield covered all home warranty contracts. The
Company was responsible for the marketing, recording sales, collecting payment
and reporting contract details and paying premiums to the insurance carriers. In
addition, the Company provided information to the insurance carriers' appointed
claims administrators who handle all claims under the Company's contracts,
including the payment of claims.
The Company commenced operations initially by marketing its extended warranty
products directly to the consumer through its web site. During fiscal 2000 the
Company developed enhanced proprietary software to facilitate more efficient
processing and tracking of online warranty transactions. This provided the
Company with the ability to deliver its products over the Internet through a
number of distribution channels by enabling it to supply a number of different
extended warranty service contracts on a co-branded or private label basis to
corporations, by embedding the Company's suite of products on such corporation's
web sites. This new capability was launched in January 2001. It was anticipated
that this would result in substantially reduced direct marketing costs for the
years ending December 31, 2001 and thereafter. As a result the Company had four
distinct distribution channels: (i) direct sales to consumers, (ii) co-branded
distribution, (iii) private label distribution and (iv) manufacturer/retailer
partnerships.
During the first half of fiscal 2001, management became concerned by the slow
progress being made by its warrantysuperstore.com business. Accordingly,
alternative strategies for the Company were evaluated by the Board of Directors,
including the acquisition of new business operations. As a result, the Company
entered into the StrandTek Transaction but, as previously reported, the closing
conditions were not met and the Exchange Agreement was terminated by written
agreement between the parties. In June 2002, management determined, in light of
continuing operating losses, to discontinue its warranty and service contract
business and to seek new business opportunities for the Company.
RECENT DEVELOPMENTS
On February 6, 2003, the Company appointed Mark Weinreb as a member of the Board
of Directors and as its President and Chief Executive Officer. The Company and
Mr. Weinreb had been exploring business plans for the Company that would involve
entering the medical sector by acquiring or participating in one or more biotech
and/or medical companies or technologies, owning one or more drugs or medical
devices that may or may not yet be available to the public, or acquiring rights
to one or more of such drugs or medical devices or the royalty streams
therefrom. Mr. Weinreb was appointed to finalize and execute the Company's new
business plan. The Company will need to recruit management, business development
and technical personnel, and develop its business model. Accordingly, it will be
necessary for the Company to raise new capital. In accordance with its business
plan, the Company raised $514,781 of capital, including $214,781, net of
expenses of $67,719, through the sale of Common Stock, and $295,000, net of
commissions of $30,000, from the sale of notes. In addition, the Company
received a total of approximately $987,000 from the settlement with the
StrandTek guarantors. A significant portion of the Standtek proceeds was used to
pay outstanding liabilities for legal expenses, employment terminations, travel
and entertainment expenses and consultants. The balance of the proceeds was used
for operating expenses and the retirement of certain debt.
On December 12, 2003, the Company signed a royalty agreement with Parallel
Solutions, Inc. "(PSI") to develop a new bioshielding platform technology for
the delivery of therapeutic proteins and small molecule drugs in order to extend
circulating half-life to improve bioavailability and dosing regimen, while
maintaining or improving pharmacologic activity. The agreement provides for PSI
to pay the Company a percentage of the revenue received from the sale of certain
specified products or licensing activity. The Company will provide capital and
guidance to PSI to conduct a proof of concept study to improve an existing
therapeutic protein with the goal of validating the bioshielding technology for
further development and licensing the technology. As of December 31, 2003, the
Company has provided $80,000 to PSI pursuant to the royalty agreement.
On January 19, 2004, the Company entered into a letter of intent with NeoStem,
Inc., a California company, whose primary business is to establish an autologous
adult stem cell bank. If a definitive agreement is reached, Phase III would
provide funding and guidance in connection with the adult stem cell banking
enterprise in exchange for a share of the revenues derived from such enterprise.
No assurances can be given that a definitive revenue sharing agreement will be
finalized, that NeoStem's collection, processing and storage technology will be
successfully implemented, that NeoStem will be able to commercialize its adult
stem cell banking enterprise, or that there will be market acceptance of any
such enterprise sufficient to generate any material revenues for NeoStem or any
material royalty revenues for the Company, or that any stem cell therapeutic
strategies will be successfully developed or commercialized.
RISK FACTORS
The risks described below are not the only risks facing the Company. Additional
risks that the Company does not yet know of or that it currently thinks are
immaterial may also impair its business operations. If any of the risks occur,
its business strategy, financial condition or operating results could be
adversely affected.
PHASE III HAS A HISTORY OF OPERATING LOSSES AND A SUBSTANTIAL ACCUMULATED
EARNINGS DEFICIT AND IT MAY CONTINUE TO INCUR LOSSES.
Since its inception in 1980, the Company has generated only limited revenues
from sales and has incurred substantial net losses of approximately $1,000,000,
$1,200,000 and $2,100,000 for the years ended December 31, 2003, 2002 and 2001,
respectively. At December 31, 2003, the Company had a stockholders' deficit of
approximately $1,500,000. The Company expects to incur additional operating
losses as well as negative cash flow from its new business operations until
revenues from the purchase of royalty interests are received.
THE COMPANY HAS LIQUIDITY PROBLEMS.
At December 31, 2003, the Company had a cash balance of $210,947, deficit
working capital of $793,749 and a stockholders' deficit of $1,502,774. In
addition, the Company sustained losses of $1,044,145, $1,159,838 and $2,033,030
for the three fiscal years ended December 31, 2003, 2002 and 2001, respectively.
The Company's lack of liquidity combined with its history of losses raises
substantial doubt as to the ability of the Company to continue as a going
concern. The financial statements of the Company do not reflect any adjustments
relating to the doubt of its ability to continue as a going concern. On
September 22, 2003, the Company commenced an equity private placement pursuant
to Regulation D to raise up to $4,000,000 through the sale of up to 40,000,000
shares of its Common Stock in increments of $5,000 or 50,000 shares. Such shares
will not be registered and will be subject to restrictions on resale. Only
selected investors which qualify as "accredited investors" as defined in Rule
501(a) under the Securities Act of 1933, as amended, were eligible to purchase
these shares. Through December 31, 2003, the Company sold 2,825,000 shares,
resulting in proceeds to the Company of $214,781, net of offering costs of
$67,719. The Company continues to offer these securities without the assistance
of an investment banker and will collect the full proceeds from any sale. From
January 1, 2004 to March 8, 2004, the Company sold an additional 400,000 shares
of its Common Stock with proceeds to the Company of $40,000 from the amended
private placement. Such shares will not be registered and will be subject to
restrictions on resale. There can be no assurance that the Company will be able
to sell sufficient quantities of these securities and may have to rely on its
ability to borrow money from new and/or existing investors. Management has sold
promissory notes in the aggregate principal amount of $75,000 which bear
interest at 20% per annum to fund the Company until such time as sufficient
proceeds are received from the private placement of its Common Stock.
THE COMPANY'S ABILITY TO CONTINUE AS A GOING CONCERN IS QUESTIONABLE.
At December 31, 2003, the Company's auditors, Holtz Rubenstein & Co., LLP,
qualified its opinion as to the Company's ability to continue as a going
concern. This qualification will make it more difficult for the Company to raise
capital on favorable terms and fund the agreements currently in place.
THE COMPANY WILL CONTINUE TO EXPERIENCE CASH OUTFLOWS.
The Company continues to incur expenses, including the salary of its new
president, rent, legal and accounting fees, insurance and general administrative
expenses. The Company's new business activities are in the development stage and
will therefore result in additional cash outflows in the coming period. The
Company commenced an amended private placement of its Common Stock to raise
additional equity to fund its current liabilities and its on-going cash needs
for working capital, its remaining obligation to PSI of $680,000, as of March
19, 2004 and to develop its planned business operations. There can be no
assurance that it will be successful in such Common Stock offering or in raising
additional funds through the issuance of notes, to satisfy the Company's needs.
Additionally, it is not possible at this time to state when the Company will
achieve a positive cash position, if at all.
THE COMPANY'S LIMITED OPERATING HISTORY MAY IMPAIR ITS ABILITY TO PLAN.
The Company's limited operating history in its planned business activities may
hinder its ability to evaluate its business and entails risks that the Company
may fail to adequately address business issues with which it has limited
experience. There is no way to predict when, if ever, the Company will achieve
profitability or positive cash flow.
BECAUSE OF ITS FINANCIAL POSITION, THERE IS SUBSTANTIAL DOUBT ABOUT ITS ABILITY
TO OPERATE AS A GOING CONCERN.
The Company has no cash generating revenues. As of December 31, 2003, the
Company had a stockholders' deficit of $1,502,774 and had a working capital
deficiency of $793,749. Although the Company recently raised $254,781 in a
Common Stock private placement offering and $75,000 from the issuance of
promissory notes to date, those funds have been substantially spent and the
Company's financial condition still raises substantial doubt about its ability
to operate as a going concern.
THE COMPANY WILL NEED ADDITIONAL FINANCING AND IS UNCERTAIN OF ITS ACCESS TO
CAPITAL FUNDING.
The Company's proposed new business will require substantial capital to identify
and make alliances with one or more pharmaceutical and/or biotechnology
companies based on the Company's current operating plan for its new business. In
addition, the Company's cash requirements may vary materially from those now
planned because of results in research, consulting with experts and modeling
sales forecasts for the potential products of potential business partners.
RISKS RELATING TO THE COMPANY'S PROPOSED NEW BUSINESS
THE COMPANY HAS ONLY ONE BUSINESS PARTNER TO DATE AND IS UNCERTAIN OF ITS FUTURE
PROFITABILITY WITH ITS INTENDED VENTURE TO GENERATE REVENUES FROM SUCH
RELATIONSHIPS.
The Company's ability to achieve profitability in its new business is dependent
in part on the agreements, if any, entered into with business partners.
Currently the Company has entered into one agreement with PSI, and since the
agreement is in its early stages, it is premature to predict any favorable
outcome. There can be no assurance that any additional agreements will be
entered into. The failure to enter into any such necessary agreements could
delay or prevent the Company's new business from achieving profitability and
would have a material adverse effect on the business, financial position and
results of operations of the Company. Further, there can be no assurance that
the Company's operations will become profitable even if the Company enters into
agreements with business partners.
THE PSI ARRANGEMENT MAY NOT BE SUCCESSFUL.
The Company's contract with its first business partner, PSI, demonstrates
certain of the risks of the Company's business. PSI is attempting to develop a
new bioshielding platform technology for the delivery of therapeutic proteins
and small molecule drugs in order to extend circulating half-life to improve
bioavailability and dosing regimen, while maintaining or improving pharmacologic
activity. The Company is providing funding and consulting services for PSI to
conduct a proof of concept study. No assurances can be given that the proof of
concept program will be successful, that any viable technology will arise from
that program, that the Company or PSI will be able to commercialize any product
or technology that is successfully developed, or that there will be market
acceptance of any such product or technology sufficient to generate any material
revenues for the Company. Even if everything is successful, it will be a long
time before the Company receives any royalty revenues from the PSI project.
THERE ARE RISKS RELATING TO POTENTIAL CORPORATE COLLABORATIONS.
The Company's new business strategy includes identifying and partnering with
various pharmaceutical and/or biotechnology companies that are developing a drug
or medical device. There can be no assurance the Company will enter into any
additional relationships with these business partners and, even if the Company
does enter into such relationships, that the arrangements will be on favorable
terms or that the Company's relationship will be successful. In some cases, the
Company will generate income from its relationship with these companies only
after its potential business partners' product has achieved significant
pre-clinical and/or clinical development, has procured requisite regulatory
approvals and/or has established its manufacturing capabilities.
The Company's potential business partners' business strategy may include
entering into collaborations or marketing and distribution arrangements with
corporate partners for the development (including clinical development),
commercialization, marketing and distribution of certain of their product
candidates. The Company's potential business partners may be dependent on such
corporate collaborations to fund clinical testing, to make certain regulatory
filings and to manufacture and market products resulting from the collaboration.
There can be no assurance that such arrangements with a corporate collaboration
will be scientifically, clinically or commercially successful. In the event that
any such arrangements are made and then terminated, such actions could adversely
affect the Company's business partners' ability to develop, commercialize,
market and distribute certain of their product candidates.
If the Company's potential business partners breach or terminate their
agreements with the Company, or fail to develop or commercialize their products
or fail to develop or commercialize their products in a timely manner, the
development of their products may be adversely affected, and thus not create an
economic benefit for the Company.
There can be no assurance that the Company's potential business partners will
not change their strategic focus or pursue alternative technologies or develop
alternative products either on their own or in collaboration with others. The
Company's business will also be affected by the effectiveness of its potential
business partners' corporate partners in marketing their products.
THERE ARE COMPANIES, UNIVERSITIES AND RESEARCH INSTITUTIONS THAT MAY BE
RESEARCHING AND TRYING TO DEVELOP PRODUCTS THAT ARE SIMILAR TO THE PRODUCTS OF
THE COMPANY'S POTENTIAL BUSINESS PARTNERS.
Competition in the medical, pharmaceutical and biotechnology industries, the
sector in which the Company plans to establish new business operations, is
intense. The Company's potential business partners may face competition from
companies with far greater financial, marketing, technical and research
resources, name recognition, distribution channels and market presence than the
Company's potential business partners who are marketing existing products or
developing new products that are similar to the products developed by the
Company's potential business partners. There can be no assurance that the
Company's potential business partners' products will be able to compete
successfully with existing products or products under development by other
companies, universities and other institutions.
THE COMPANY'S POTENTIAL BUSINESS PARTNERS MAY DEPEND ON THIRD PARTIES.
The Company's potential business partners may rely entirely on third parties for
a variety of functions, including certain functions relating to research and
development, manufacturing, clinical trials management, regulatory affairs and
sales, marketing and distribution. There can be no assurance that the Company's
potential business partners will be able to establish and maintain any of these
relationships on acceptable terms or enter into these arrangements without undue
delays or expenditures. In addition, the business partners may require, and seek
to raise, additional capital with third parties in order to develop products and
meet their working capital needs. There is no guarantee that the business
partners will be able to raise such additional capital, and any agreements
previously made between the business partners and the Company may make the
business partners less attractive to third parties in this regard.
THERE ARE UNCERTAINTIES ASSOCIATED WITH PRE-CLINICAL AND CLINICAL TESTING.
The grant of regulatory approvals for the commercial sale of any of the
Company's potential business partners' potential products will depend in part on
the Company's potential business partners and/or their collaborators
successfully conducting extensive pre-clinical and clinical testing to
demonstrate their products safety and efficacy in humans. The results of
pre-clinical studies by the Company's potential business partners and/or their
collaborators may be inconclusive and may not be indicative of results that will
be obtained in human clinical trials. In addition, results attained in early
human clinical trials relating to the products under development by the
Company's potential business partners may not be indicative of results that will
be obtained in later clinical trials. As results of particular pre-clinical
studies and clinical trials are received, the Company's potential business
partners and/or their collaborators may abandon projects with which the Company
assisted in developing which they might otherwise have believed to be promising.
The Company's potential business partners may be involved in developing drugs on
which they plan to file investigational new drug applications ("INDs") with the
FDA or make equivalent filings outside of the United States. There can be no
assurance that necessary pre-clinical studies on these products will be
completed satisfactorily, if at all, or that the Company's potential business
partners otherwise will be able to make their intended filings. Clinical testing
is very expensive, and the Company's potential business partners and/or their
collaborators will have to devote substantial resources for the cost of clinical
trials.
The Company's potential business partners may have no experience in conducting
clinical trials and may have to rely, in part, on academic institutions and on
clinical research organizations to conduct and monitor certain clinical trials.
There can be no assurance that such entities will conduct the clinical trials
successfully.
Failure to commence or complete any planned clinical trials by the Company's
potential business partners would have a material adverse effect on the
Company's new business.
THE COMPANY'S POTENTIAL BUSINESS PARTNERS AND THEIR PRODUCTS WILL BE SUBJECT TO
GOVERNMENT REGULATIONS AND THERE IS NO ASSURANCE OF REGULATORY APPROVAL.
The Company's potential business partners and their products will be subject to
comprehensive regulation by the FDA in the United States and by comparable
authorities in other countries. These national agencies and other federal,
state, and local entities regulate, among other things, the pre-clinical and
clinical testing, safety, effectiveness, approval, manufacture, labeling,
marketing, export, storage, record keeping, advertising, and promotion of the
Company's potential business partners' products.
The process of obtaining FDA approvals can be costly, time consuming, and
subject to unanticipated delays and the Company's potential business partners
may have had only limited experience in filing and pursuing applications
necessary to gain regulatory approvals. There can be no assurance that such
approvals will be granted on a timely basis, or at all.
The Company's potential business partners may also be subject to numerous and
varying foreign regulatory requirements governing the design and conduct of
clinical trials and the managing and marketing of their products. The approval
procedure varies among countries and can involve additional testing, and the
time required to obtain approval may differ from that required to obtain FDA
approval.
There can be no assurance that the Company's potential business partners or
their partners will qualify for regulatory approvals or receive necessary
approvals to commercialize product candidates in any market. Delays in receipt
of or failure to receive regulatory approvals, or the loss of previously
received approvals, would have a material adverse effect on the Company's
potential business partners' business, and therefore, on the Company's business.
THE COMPANY'S NEW VENTURE MAY REQUIRE IT TO REGISTER AS AN INVESTMENT COMPANY
UNDER THE INVESTMENT COMPANY ACT OF 1940.
The Company is not registered as an investment company under the Investment
Company Act of 1940, as amended (or any similar state laws) (the "Company Act").
The Company does not believe (i) it is an "investment company" pursuant to the
Company Act, or (ii) that it will hold "securities" pursuant to the Company Act
or the Securities Act of 1933, as amended. However, the Securities and Exchange
Commission ("SEC") may disagree with the Company's position and deem the Company
to be an "investment company" under the Company Act and require the Company to
register as an investment company. If this were to occur, the Company's
day-to-day operations would become subject to the regulatory and disclosure
requirements imposed by the Company Act. The Company does not have the
infrastructure to operate as an investment company. The Company has sought
guidance from the SEC staff with respect to this issue. No assurance can be
given that the staff will respond favorably.
RISKS RELATING TO INTELLECTUAL PROPERTY
IF THE COMPANY OR ITS BUSINESS PARTNERS ARE UNABLE TO OBTAIN PATENT PROTECTION
FOR THE PRODUCTS THAT RESULT FROM THE MEDICAL DEVELOPMENT BUSINESS, THE VALUE OF
THE MEDICAL DEVELOPMENT BUSINESS WILL BE ADVERSELY AFFECTED. IF THE COMPANY OR
ITS BUSINESS PARTNERS INFRINGE PATENT OR OTHER INTELLECTUAL PROPERTY RIGHTS OF
THIRD PARTIES, THEY MAY NOT BE ABLE TO DEVELOP AND COMMERCIALIZE THE PRODUCTS
AND SERVICES THAT WILL COMPRISE THE MEDICAL DEVELOPMENT BUSINESS OR THE COST OF
DOING SO MAY INCREASE.
Patent positions of pharmaceutical and biotechnology companies are generally
uncertain and involve complex legal, scientific and factual questions. The
ability of the Company or its business partners to develop and commercialize
products and services depends in significant part on the Company's or its
business partners' ability to (i) obtain patents, (ii) obtain licenses to the
proprietary rights of others on commercially reasonable terms, (iii) operate
without infringing upon the proprietary rights of others, (iv) prevent others
from infringing on the Company's or its business partners' proprietary rights,
and (v) protect trade secrets.
THERE IS SIGNIFICANT UNCERTAINTY ABOUT THE VALIDITY AND PERMISSIBLE SCOPE OF
PATENTS IN THE PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRY, WHICH MAY MAKE IT
DIFFICULT FOR THE COMPANY OR ITS BUSINESS PARTNERS TO OBTAIN PATENT PROTECTION
FOR DISCOVERIES.
The validity and permissible scope of patent claims in the pharmaceutical and
biotechnology fields, including the genomics field, involve important unresolved
legal principles and are the subject of public policy debate in the United
States and abroad. There is also some uncertainty as to whether human clinical
data will be required for issuance of patents for human therapeutics. If the
Company is involved in a project in this field and if such data are required,
the Company's or its business partners' ability to obtain patent protection
could be delayed or otherwise adversely affected.
THIRD PARTIES MAY OWN OR CONTROL PATENTS OR PATENT APPLICATIONS AND REQUIRE THE
COMPANY OR ITS BUSINESS PARTNERS TO SEEK LICENSES, WHICH COULD INCREASE THE
COMPANY'S OR ITS BUSINESS PARTNERS' DEVELOPMENT AND COMMERCIALIZATION COSTS, OR
PREVENT THE COMPANY OR ITS BUSINESS PARTNERS FROM DEVELOPING OR MARKETING THE
COMPANY'S OR ITS BUSINESS PARTNERS' PRODUCTS OR SERVICES.
The Company or its business partners may not have rights under some patents or
patent applications related to some of their existing or proposed products,
processes or services. Third parties may own or control these patents and patent
applications in the United States and abroad. Therefore, in some cases, in order
to develop, manufacture, sell or import some of the Company's or its business
partners' existing and proposed products, processes or services, the Company or
its business partners may choose to seek, or be required to seek, licenses under
third-party patents issued in the United States and abroad or those that might
issue from United States and foreign patent applications. In such event, the
Company or its business partners would be required to pay license fees or
royalties or both to the licensor. If licenses are not available to the Company
or its business partners on acceptable terms, the Company or its business
partners may not be able to develop, manufacture, sell or import these products,
processes or services.
THE COMPANY OR ITS BUSINESS PARTNERS MAY BECOME INVOLVED
IN EXPENSIVE PATENT LITIGATION OR OTHER PROCEEDINGS, WHICH COULD RESULT IN THE
COMPANY OR ITS BUSINESS PARTNERS INCURRING SUBSTANTIAL COSTS AND EXPENSES OR
SUBSTANTIAL LIABILITY FOR DAMAGES OR REQUIRE THE COMPANY OR ITS BUSINESS
PARTNERS TO STOP THEIR DEVELOPMENT AND COMMERCIALIZATION EFFORTS.
There has been substantial litigation and other proceedings regarding the patent
and other intellectual property rights in the pharmaceutical and biotechnology
industries. The Company or its business partners may become a party to patent
litigation or other proceedings regarding intellectual property rights.
The cost to the Company or its business partners of any patent litigation or
other proceeding, even if resolved in the Company's or its business partners'
favor, could be substantial. Some of the Company's or its business partners'
competitors may be able to sustain the cost of such litigation or proceedings
more effectively than the Company or its business partners because of their
substantially greater financial resources. If a patent litigation or other
proceeding is resolved against the Company or its business partners, the Company
or its business partners may be enjoined from developing, manufacturing, selling
or importing their products, processes or services without a license from the
other party and the Company or its business partners may be held liable for
significant damages. The Company or its business partners may not be able to
obtain any required license on commercially acceptable terms or at all.
Uncertainties resulting from the initiation and continuation of patent
litigation or other proceedings could have a material adverse effect on the
Company's or its business partners' ability to compete in the marketplace.
Patent litigation and other proceedings may also absorb significant management
time.
COMPETITION
Competition in the medical, pharmaceutical and biotechnology industries, the
sector in which the Company plans to establish new business operations, is
intense. The Company's potential business partners may face competition from
companies with far greater financial, marketing, technical and research
resources, name recognition, distribution channels and market presence than the
Company's potential business partners who are marketing existing products or
developing new products that are similar to the products developed by the
Company's potential business partners. There can be no assurance that the
Company's potential business partners' products will be able to compete
successfully with existing products or products under development by other
companies, universities and other institutions.
EMPLOYEES
As of December 31, 2003, the Company had one employee.
ITEM 2. PROPERTIES
On February 21, 2003 the Company leased office space in Melville, New York at an
original annual rental of $18,000. The lease has been extended for an additional
twelve months and expires on March 31, 2005. The annual rental increases to
approximately $19,200 on April 1, 2004 and continues until the expiration date.
This space will be sufficient for the Company's needs until the business plan of
the Company has been successfully executed.
ITEM 3. LEGAL PROCEEDINGS
As discussed in Note 3 of the accompanying notes to the financial statements,
StrandTek defaulted on the payment of $1,250,000 plus accrued interest due to
the Company on July 31, 2002. The Company ceased accruing interest as of July
31, 2002 for financial statement purposes. As a result, on August 6, 2002, the
Company filed a complaint in the Superior Court of New Jersey entitled Corniche
Group Incorporated v StrandTek International, Inc., a Delaware corporation,
StrandTek International, Inc., a Florida corporation, David M. Veltman, William
G. Buckles Jr., Jerome Bauman and Jan Arnett. The complaint sought recovery of
the $1,250,000 loan, plus interest, costs and fees, and sought recovery against
the individual defendants pursuant to their partial guarantees.
Between July 2003 and December 2003, guarantors Veltman, Buckles and Arnett paid
their judgments in full, with payments totaling approximately $295,000, $295,000
and $297,000 respectively. In December 2003, the Company settled with defendant
Bauman for a payment of $100,000. These payments, totaling approximately
$987,000, complete the transaction.
The Company is not aware of any material pending legal proceedings or claims
against the Company.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
No matters were submitted to a vote of the Company's stockholders during the
fourth quarter of 2003.
PART II
ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
(a) Market Information. The Company's Common Stock is traded on the OTC
Bulletin Board under the symbol "PHSM" since July 24, 2003. Prior to
that date, the Company's Common Stock traded under the symbol "CNGI."
The following table sets forth the high and low bid prices of the
Company's Common Stock for each quarterly period within the two most
recent fiscal years and the most recent quarter, as reported by Nasdaq
Trading and Market Services. On March 8, 2004, the closing bid price
for the Company's Common Stock was $0.14. Information set forth in the
table below represents inter-dealer prices without retail mark-up,
mark-down, or commission, and may not necessarily represent actual
transactions.
2003 High Low
First Quarter $ 0.13 $ 0.03
Second Quarter 0.15 0.06
Third Quarter 0.31 0.08
Fourth Quarter 0.31 0.11
2002 High Low
First Quarter $ 0.68 $ 0.35
Second Quarter 0.37 0.06
Third Quarter 0.09 0.05
Fourth Quarter 0.10 0.04
(b) Holders. As of March 8, 2004, there were approximately 1,068 holders
of record of the Company's Common Stock. -------
(c) Dividends. Holders of Common Stock are entitled to dividends when, as,
and if declared by the Board of Directors out of funds legally
available therefor. The Company has not paid any cash dividends on its
Common Stock and, for the foreseeable future, intends to retain future
earnings, if any, to finance the operations, development and expansion
of its business. Future dividend policy is subject to the discretion of
the Board of Directors.
SERIES A PREFERRED STOCK
The Certificate of Designation for the Company's Series A Preferred Stock
provides that at any time after December 1, 1999 any holder of Series A
Preferred Stock may require the Company to redeem his shares of Series A
Preferred Stock (if there are funds with which the Company may legally do so) at
a price of $1.00 per share. Notwithstanding the foregoing redemption provisions,
if any dividends on the Series A Preferred Stock are past due, no shares of
Series A Preferred Stock may be redeemed by the Company unless all outstanding
shares of Series A Preferred Stock are simultaneously redeemed. The holders of
Series A Preferred Stock may convert their Series A Preferred Stock into shares
of Common Stock of the Company at a price of $5.20 per share.
On January 29, 2002 notice was given that, pursuant to the Company's Restated
Certificate of Incorporation, as amended, the Company has called for redemption
and will redeem (the "Redemption") on the date of the closing of the StrandTek
Transaction (the "Redemption Date"), all shares of the Company's Series A
Convertible Preferred Stock outstanding on that date at a redemption price of
$1.05, plus accrued and unpaid dividends from July 1, 1995 through and including
the Redemption Date of approximately $0.47 per share. The Redemption, among
other financial, legal and business conditions, was a condition precedent to the
closing of the StrandTek Transaction. Similarly, completion of the Redemption
was subject to closing the StrandTek Transaction. Upon termination of the
StrandTek Transaction, the Company rescinded the Notice of Redemption.
At December 31, 2003, 681,174 shares of Series A Preferred Stock were
outstanding. If the preferred shareholders do not convert their shares into
Common Stock, and if the Company were required to redeem any significant number
of shares of Series A Preferred Stock, the Company's financial condition may be
materially affected.
RECENT SALES OF UNREGISTERED SECURITIES
In September 2002, the Company sold to accredited investors, pursuant to
Regulation D, five 60-day promissory notes in the principal sum of $25,000 each,
resulting in net proceeds to the Company of $117,500, net of offering costs. The
notes bear interest at 15% per annum payable at maturity. The terms of the notes
include a default penalty pursuant to which if the notes are not paid on the due
date, the holder shall have the option to purchase 25,000 shares of the
Company's Common Stock for an aggregate purchase price of $125. If the non
payment continues for 30 days, then on the 30th day, and at the end of each
successive 30-day period until the note is paid in full, the holder has the
option to purchase an additional 25,000 shares of the Company's Common Stock for
an aggregate purchase price of $125. As of December 31, 2003 a total of
1,000,000 of such shares resulting in net proceeds to the Company of $5,000 were
exercised because the notes remain unpaid. Options to purchase an additional
650,000 shares of Common Stock at an aggregate purchase price of $3,250 have
been granted pursuant to the default penalty. Subsequent to December 31, 2003,
200,000 shares of Common Stock were purchased resulting in net proceeds to the
Company of $1,000.
In February 2003, the Company sold to accredited investors, pursuant to
Regulation D, a series of 30-day promissory notes in the aggregate principal sum
of $50,000. The notes bear interest at 20% per annum payable at maturity. In
November 2003, the Company repaid all $50,000 of such promissory notes together
with all accrued interest of $6,854.
On March 17, 2003, the Company commenced a private placement offering, pursuant
to Regulation D, to raise up to $250,000 in 6-month promissory notes in
increments of $5,000 bearing interest at 15% per annum. Only selected investors
which qualify as "accredited investors" as defined in Rule 501(a) under the
Securities Act of 1933, as amended, were eligible to purchase these promissory
notes. The Company raised the full $250,000 through the sale of such promissory
notes, resulting in net proceeds to the Company of $225,000, net of offering
costs. The note contains a default provision which raises the interest rate to
20% if the notes are not paid when due. The Company issued $250,000 of these
notes and as of December 31, 2003, $60,000 of the principle amount of these
notes was in default. All interest payments have been made and are current.
On September 22, 2003, the Company commenced an equity private placement
pursuant to Regulation D to raise up to $4,000,000 through the sale of up to
40,000,000 shares of its Common Stock in increments of $5,000 or 50,000 shares.
Such shares will not be registered and will be subject to restrictions on
resale. Only selected investors which qualify as "accredited investors" as
defined in Rule 501(a) under the Securities Act of 1933, as amended, were
eligible to purchase these shares. The placement closed on December 31, 2003
upon the sale of 2,825,000 shares, resulting in proceeds to the Company of
$214,781, net of offering costs of $67,719.
The Company amended its equity private placement (see Note 7) pursuant to
Regulation D to raise up to $4,000,000 through the sale of up to 40,000,000
shares of Common Stock in increments of $5,000 or 50,000 shares. Such shares
will not be registered and will be subject to restrictions on resale. Only
selected investors which qualify as "accredited investors" as defined in Rule
501(a) under the Securities Act of 1933, as amended, are eligible to purchase
these shares. The initial placement closed on December 31, 2003. The amended
private placement does not include any investment banking fees and therefore all
proceeds, less expenses such as printing, transfer fees, etc., will be paid
directly to the Company. The previous investment banker, Robert M. Cohen &
Company, has been fully paid for its efforts. As of March 8, 2004, 400,000
shares have been sold with proceeds to the Company of $40,000.
In February 2004, the Company sold 30 day 20% notes pursuant to Regulation D in
the amount of $75,000 to two accredited investors to fund current operations. It
is anticipated that these notes will be repaid from the proceeds of the amended
equity private placement. These notes have a default provision that if they are
not paid within 30 days, there is an additional interest payment of $250 per
$25,000 for each 30 day period or part thereof.
In March 2004, the Company sold a 30 day 20% note pursuant to Regulation D in
the amount of $50,000 to a director who qualifies as an accredited investor to
fund current operations. It is anticipated that this note will be repaid when
sufficient proceeds of the amended equity private placement are received.
ITEM 6...SELECTED FINANCIAL DATA
The selected statements of operations and balance sheet data set forth below are
derived from audited financial statements of the Company. The information set
forth below should be read in conjunction with the Company's audited financial
statements and notes thereto. See Item 8 "Financial Statements and Supplementary
Data" and Item 7 "Management's Discussion and Analysis of Financial Condition
and Results of Operation". On February 4, 1999 the Company changed its fiscal
year-end from March 31 each year to December 31 each year. The selected
financial data set out below has not been retroactively restated to reflect such
change in fiscal year-end date and accordingly is presented as historically
reported in the financial statements of the Company.
Statement of Operations: Year Ended Year Ended Year Ended Year Ended Year Ended
($'000 except net loss per share which is December 31, December 31, December 31, December 31, December 31,
stated in $) 2003 2002 2001 2000 1999
Earned revenues $ 65 $ 81 $ 107 $ 27 $ -
Direct costs 44 60 70 33 -
Gross profit 21 21 37 (6) -
Operating (loss) (894) (1,149) (1,606) (2,516) (1,023)
Loss before discontinued operations and
preferred dividends (1,044) (1,160) (1,792) (2,296) (1,084)
Net loss attributable to common
stockholders (1,068) (1,208) (2,081) (2,075) (1,170)
Basic and diluted earnings per share:
Loss from continuing operations (0.05) (0.05) (0.08) (0.16) (0.16)
Income (loss) from discontinued operations - - (0.01) (0.02) -
Net loss attributable to common
shareholders (0.05) (0.05) (0.09) (0.14) (0.17)
Weighted average number of shares
outstanding 23,509,343 22,344,769 22,284,417 14,902,184 6,905,073
Balance Sheet Data: As of As of As of As of As of
$'000 December 31, December 31, December 31, December 31, December 31,
2003 2002 2001 2000 1999
Working Capital (Deficiency) $ (794) $ (82) $ 1,085 $ 2,079 $ 3,192
Total Assets 312 1,183 1,836 3,757 4,905
Current Liabilities 1,023 1,141 489 458 868
(Accumulated Deficit) (10,762) (9,694) (8,486) (6,406) (4,302)
Total Stockholders' (Deficit)/Equity (1,503) (824) 373 2,450 3,140
Selected Quarterly Financial Data
$'000 Quarter Quarter Quarter Quarter Quarter Quarter Quarter Quarter Quarter
(except net loss per share Ended Ended Ended Ended Ended Ended Ended Ended Ended
which is stated in $) 12/31/03 9/30/03 6/30/03 3/31/03 12/31/02 9/30/02 6/30/02 3/31/02 12/31/01
Earned Revenues $ 15 $ 15 $ 17 $ 18 $ 19 $ 20 $ 18 $ 24 $ 42
Direct Costs 8 11 12 13 13 14 14 19 17
Gross profit 7 4 5 5 5 6 5 5 25
Operating Loss (369) (197) (205) (123) (357) (225) (201) (366) (449)
Net Loss Attributable to
Common Stockholders (437) (216) (260) (155) (389) (231) * (246) (342) * (725)
Net loss per share (0.02) (0.01) (0.01) (0.01) - (0.01) (0.01) (0.02) (0.03)
$'000 Quarter Quarter Quarter
(except net loss per share Ended Ended Ended
which is stated in $) 9/30/01 6/30/01 3/31/01
Earned Revenues $ 33 $ 21 $ 11
Direct Costs 31 15 7
Gross profit 2 6 4
Operating Loss (386) (353) (418)
Net Loss Attributable to
Common Stockholders (374) (329) (653)
Net loss per share (0.02) (0.01) (0.03)
* Includes write-off of unamortized capitalized software in fiscal 2001 of
$305,333 and property and equipment impairment charges of $54,732 in fiscal
2002.
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATION
The following discussion should be read in conjunction with the audited
financial statements and notes thereto, included in Item 8 of this report, and
is qualified in its entirety by reference thereto.
GENERAL
During the first half of fiscal 2001, management became concerned by the slow
progress being made by its warrantysuperstore.com business. Accordingly,
alternative strategies for the Company were evaluated by the Board of Directors,
including the acquisition of new business operations. As a result, on January 7,
2002 the Company entered into the StrandTek Transaction as previously reported.
Consummation of the StrandTek Transaction was conditioned upon certain closing
conditions, including the Company obtaining financing via an equity private
placement, which ultimately could not be met and as a result in June 2002, the
Exchange Agreement was formally terminated by written agreement between the
Company and StrandTek. In June 2002, management also determined, in light of
continuing operating losses, to discontinue its warranty and service contract
business and to seek new business opportunities for the Company.
NEW BUSINESS OPPORTUNITIES
Management had been exploring new business opportunities for the Company and on
February 6, 2003, the Company appointed Mark Weinreb as a member of the Board of
Directors and as its President and Chief Executive Officer. The Company and Mr.
Weinreb had been exploring business plans for the Company that may involve,
under the name "Phase III Medical, Inc.", entering the medical sector by
acquiring or participating in one or more biotech and/or medical companies or
technologies, owning one or more drugs or medical devices that may or may not
yet be available to the public, or acquiring rights to one or more of such drugs
or medical devices or the royalty streams therefrom. Mr. Weinreb was appointed
to finalize and execute the Company's new business plan. The Company will need
to recruit management, business development and technical personnel, and develop
its business model. Accordingly, it will be necessary for the Company to raise
new capital. There can be no assurance that any such business plan developed by
the Company will be successful, that the Company will be able to acquire such
new business or rights or raise new capital, or that the terms of any
transaction will be favorable to the Company.
RESULTS OF CONTINUING OPERATIONS
The Company's "Significant Accounting Policies" are described in Note 2 to the
audited financial statements and notes thereto, included in Item 8 of this
report. The Company recognizes revenue from its warranty service contracts
ratably over the length of the contracts executed. Additionally, the Company
purchased insurance to fully cover any losses under the service contracts from a
domestic carrier. The insurance premium expense and other costs related to the
sale are amortized ratably over the life of the contracts.
FISCAL 2003 COMPARED TO FISCAL 2002
The Company generated recognized revenues from the sale of extended warranties
and service contracts via the Internet of $65,000 in fiscal 2003. The revenues
generated in the year were derived almost entirely from revenues deferred over
the life of the contracts sold in prior years. Similarly, direct costs of
$44,000 incurred in fiscal 2003, relate to costs previously deferred over the
life of such contracts.
General and administrative expenses totaled $685,000 during the year ended
December 31, 2003 as compared to $912,000 for fiscal 2002, a decrease of
$227,000 or 24.9%. The decrease was primarily attributable to decreases in
employee termination costs ($145,000), legal ($86,000), travel and entertainment
($65,000), directors fees ($25,000), rents ($33,000) and depreciation ($16,000)
partially offset by increases in insurance ($66,000) and salaries as a result of
the employment agreement by and between the Company and Mark Weinreb ($41,000).
Costs generally were significantly lower as the Company wound down its
operations and closed its office facilities in Texas in July 2002.
The Company realized a loss from the unsecured, un-guaranteed note receivable
from StrandTek of $150,000 in fiscal 2003. Through March 1, 2004, the Company
made payments to PSI of $240,000. The Company's minimum commitment to PSI
pursuant to the royalty agreement with PSI is $1,000,000.
Interest income increased by $18,000 to $89,000 in fiscal 2003 as compared to
fiscal 2002 due to the collection of the StrandTek note receivable and the
additional funds received from the sale of Common Stock and notes. Interest
expense increased in fiscal 2003 to $215,000 from $23,000 in fiscal 2002 due to
the higher level of debt and certain debt being in default and therefore subject
to a higher interest rate. In addition, the Company recorded interest expense in
fiscal 2003 relating to the Series A preferred in the amount of approximately
$24,000 due to a recent accounting pronouncement.
For the reasons cited above, the net loss before preferred stock dividend
decreased to $1,044,000 in fiscal 2003 from the comparable loss of $1,160,000
for fiscal 2002.
FISCAL 2002 COMPARED TO FISCAL 2001
The Company generated recognized revenues from the sale of extended warranties
and service contracts via the Internet of $81,000 in fiscal 2002. The revenues
generated in the year were derived almost entirely from revenues deferred over
the life of the contracts sold in prior years. Similarly, direct costs of
$61,000 incurred in fiscal 2002, relate to costs previously deferred over the
life of such contracts. Revenues in fiscal 2001 totaled $225,000 of which
$107,000 were recognized as earned revenues, the balance deferred over the life
of the contracts sold. Direct costs in fiscal 2001 totaled $71,000.
General and administrative expenses totaled $912,000 during the year ended
December 31, 2002 as compared to $1,643,000 for fiscal 2001, a decrease of
$731,000 or 44.5%. Costs generally were significantly lower as the Company wound
down its operations and closed its office facilities in Texas in July 2002. As a
result, selling, general and administrative expenses in fiscal 2002 are not
comparable to fiscal 2001 when the Company incurred operating expenses such as
advertising and significantly higher payroll costs. One time employee
termination and general closure costs totaling approximately $150,000 were
incurred in fiscal 2002 and an impairment charge of $55,000 was recorded in June
2002 to adjust property and equipment to its net realizable value.
In the year ended December 31, 2002, the Company provided an allowance for the
unsecured, un-guaranteed note receivable from StrandTek of $250,000 plus accrued
interest of $8,103.
Interest income decreased by $36,000 to $71,000 in fiscal 2002 as compared to
fiscal 2001 because interest income from the StrandTek loans, accrued through
July 31, 2002 was less than interest earned from investments in marketable
securities in fiscal 2001. Interest expense increased from $6,000 in the year
ended December 31, 2001 to $23,000 in fiscal 2002 primarily due to the
short-term loans secured in September 2002 to fund the Company's operating
expenses.
For the reasons cited above, net loss before preferred stock dividend decreased
by 35.3% to $1,160,000 in 2002 from the comparable loss of $1,792,000 for fiscal
2001.
LIQUIDITY AND CAPITAL RESOURCES
The following chart represents the net funds provided by or used in operating,
financing and investment activities for each period as
indicated:
Twelve Months Ended
-------------------
December 31, 2003 December 31, 2002
Cash provided by (used in)
operating activities $ (1,021,913) $ 1,005,376
Cash provided by (used in)
investing activities 847,419 (1,247,338)
Cash provided by (used in)
financing activities 366,186 209,949
At December 31, 2003, the Company had a cash balance of $210,947, deficit
working capital of $793,749 and a stockholders' deficit of $1,502,774. In
addition, the Company sustained losses of $1,044,145, $1,159,838 and $2,033,030
for the three fiscal years ended December 31, 2003, 2002 and 2001, respectively.
The Company's lack of liquidity combined with its history of losses raises
substantial doubt as to the ability of the Company to continue as a going
concern. On September 22, 2003 the Company commenced an equity private placement
pursuant to Regulation D to raise up to $4,000,000 through the sale of up to
40,000,000 shares of its Common Stock in increments of $5,000 or 50,000 shares.
Such shares will not be registered and will be subject to restrictions on
resale. Only selected investors which qualify as "accredited investors" as
defined in Rule 501(a) under the Securities Act of 1933, as amended, were
eligible to purchase these shares. Through December 31, 2003, the Company sold
2,825,000 shares, resulting in proceeds to the Company of $214,781, net of
offering costs of $67,719. The Company continues to offer these securities
without the assistance of an investment banker and will collect the full
proceeds from any sale. As of March 8, 2004, the Company has sold 400,000 shares
of its Common Stock with proceeds to the Company of $40,000 from the amended
private placement. There can be no assurance that the Company will be able to
sell sufficient quantities of these securities and may have to rely on its
ability to borrow money from new and/or existing investors. Management has sold
promissory notes which bear interest at 20% per annum to fund the Company until
such time as sufficient proceeds are received from the private placement of its
Common Stock.
The following table reflects a summary of the Company's contractual cash
obligations as of December 31, 2003:
Payments due by period
Contractual Obligations Less than More than
Total 1 year 1-3 years 3-5 years 5 years
Long-term debt obligations $ 9,513 $ 9,513 $ 0 $ 0 $ 0
Notes payable 400,000 400,000 0 0 0
Operating leases 23,700 18,900 4,800 0 0
Employment agreement 438,846 199,500 239,346 0 0
Purchase obligations 920,000 920,000 0 0 0
------- ------- -------- -- --
Total $1,792,059 $1,547,913 $244,146 $ 0 $ 0
========= ========= ======== == ==
INFLATION
The Company does not believe that its operations have been materially influenced
by inflation in the fiscal year ended December 31, 2003, a situation which is
expected to continue for the foreseeable future.
SEASONALITY
The Company does not believe that its operations are seasonal in nature.
OFF-BALANCE SHEET ARRANGEMENTS
The Company does not have any off-balance sheet arrangements.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET
RISK
Not Applicable.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
The financial statements and supplementary financial information required to be
filed under this Item are presented commencing on page F-1 of the Annual Report
on Form 10-K, and are incorporated herein by reference.
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING
AND FINANCIAL DISCLOSURE
As previously reported on the Company's Form 8-K filed January 8, 2004, as
amended on February 3, 2004, on January 6, 2004, upon recommendation and
approval of the Company's and Board of Directors, the Company dismissed Travis,
Wolff & Company, LLP ("Travis Wolff") and engaged Holtz Rubenstein & Co., LLP
("Holtz") as the Company's independent auditors for the fiscal year ended
December 31, 2003.
Travis Wolff's reports on the Company's financial statements for each of the
years ended December 31, 2002 and 2001 contained a qualified opinion as to the
uncertainty of the Company's ability to continue as a going concern. No
modifications were made to the financial statements as a result of this
uncertainty.
During the years ended December 31, 2002 and 2001 and through January 6, 2004,
there were no disagreements with Travis Wolff on any matter of accounting
principles or practices, financial statement disclosure, or auditing scope or
procedure which if not resolved to Travis Wolff's satisfaction, would have
caused them to make reference to the subject matter in connection with their
report on the Company's financial statements for such years; and there were no
reportable events as defined in Item 304(a)(1)(v) of Regulation S-K.
During the years ended December 31, 2002 and 2001 and through January 6, 2004,
the Company did not consult Holtz with respect to the application of accounting
principles as to a specified transaction, either completed or proposed, or the
type of audit opinion that might be rendered on the Company's financial
statements, or any other matters or reportable events as set forth in Items
304(a)(2)(i) and (ii) of Regulation S-K.
ITEM. 9A. CONTROLS AND PROCEDURES
DISCLOSURE CONTROLS AND PROCEDURES
As of the end of the Company's most recently completed fiscal quarter (the
registrant's fourth fiscal quarter in the case of an annual report) covered by
this report, the Company carried out an evaluation, with the participation of
the Company's management, including the Company's Chief Executive Officer, of
the effectiveness of the Company's disclosure controls and procedures pursuant
to Securities Exchange Act Rule 13a-15. Based upon that evaluation, the
Company's Chief Executive Officer concluded that the Company's disclosure
controls and procedures are effective in ensuring that information required to
be disclosed by the Company in the reports that it files or submits under the
Securities Exchange Act is recorded, processed, summarized and reported, within
the time periods specified in the SEC's rules and forms.
CHANGES IN INTERNAL CONTROLS OVER FINANCIAL REPORTING
There have been no changes in the Company's internal controls over financial
reporting that occurred during the Company's last fiscal quarter to which this
report relates that have materially affected, or are reasonably likely to
materially affect, the Company's internal control over financial reporting.
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
The following table sets forth certain information regarding the directors and
executive officers of the Company as of March 8, 2004:
Name Age Position
- ---- --- --------
Mark Weinreb 51 Director, President & Chief Executive Officer
Wayne Marasco 50 Director
Joseph Zuckerman 52 Director
Michael Lax 50 Director
Mark Weinreb
Chief Executive Officer
Mr. Weinreb joined the Company on February 6, 2003 as a Director, Chief
Executive Officer and President. In 1976, Mr. Weinreb joined Bio Health
Laboratories, Inc., a state-of-the-art medical diagnostic laboratory providing
clinical testing services for physicians, hospitals, and other medical
laboratories. He progressed to become the laboratory administrator in 1978 and
then an owner and the laboratory's Chief Operating Officer in 1982. Here he
oversaw all technical and business facets, including finance, laboratory science
technology and all the additional support departments. He left Bio Health Labs
in 1989 when he sold the business to a biotechnology company listed on the New
York Stock Exchange. In 1992, Mr. Weinreb founded Big City Bagels, Inc., a
national chain of franchised upscale bagel bakeries and became Chairman and
Chief Executive Officer of such entity. The company went public in 1995 and in
1999 he redirected the company and completed a merger with an Internet service
provider. In 2000, Mr. Weinreb became the Chief Executive Officer of Jestertek,
Inc., a 12-year old software development company pioneering gesture recognition
and control using advanced inter-active proprietary video technology. In 2002,
he left Jestertek after arranging additional financing. Mr. Weinreb received a
Bachelor of Arts degree in 1975 from Northwestern University and a Master of
Science degree in 1982 in Medical Biology, from C.W. Post, Long Island
University.
Wayne Marasco, M.D., Ph.D.
Director
Dr. Marasco joined the Board of Directors of the Company in June 2003. Dr.
Marasco is an Associate Professor in the Department of Cancer Immunology & AIDS
at the Dana-Farber Cancer Institute and Associate Professor of Medicine in the
Department of Medicine, Harvard Medical School. Dr. Marasco is a board-certified
physician specializing in the treatment of infectious diseases. His clinical
sub-specialty is in the treatment of immunocompromised (cancer, bone marrow and
solid organ transplants) and HIV-1 infected patients.
The Marasco research laboratories are primarily focused on the areas of antibody
engineering and gene therapy. New immuno- and genetic- therapies for HIV-1
infection / AIDS, HTLV-1, the etiologic agent in Adult T-cell Leukemia, and
other emerging infectious diseases are being studied. Dr. Marasco's laboratory
is recognized internationally for its pioneering development of intracellular
antibodies (sFv) or "intrabodies" as a new class of molecules for research and
gene therapy applications. He is the author of more than 70 peer reviewed
research publications, numerous chapters, books and monographs and has been an
invited speaker at many national and international conferences in the areas of
antibody engineering, gene therapy and AIDS. Dr. Marasco is also the Scientific
Director of the National Foundation for Cancer Research (NFCR) Center for
Therapeutic Antibody Engineering. The NFCR Center is located at the Dana-Faber
Cancer Institute and will work with investigators globally to develop new human
monoclonal antibody drugs for the treatment of human cancers.
In 1995, Dr. Marasco founded IntraImmune Therapies, Inc., a gene therapy and
antibody engineering company. He served as the Chairman of the Scientific
Advisory Board until the company was acquired by Abgenix in 2000. He has also
served as a scientific advisor to several biotechnology companies working in the
field of antibody engineering, gene discovery and gene therapy. He is an
inventor on numerous issued and pending patent applications.
Joseph Zuckerman, M.D.
Director
Joseph D. Zuckerman joined the Board of Directors of the Company in January
2004. Since 1997, Dr. Zuckerman has been Chairman of the NYU-Hospital for Joint
Diseases Department of Orthopaedic Surgery and the Walter A. L. Thompson
Professor of Orthopaedic Surgery at the New York University School of Medicine.
He is responsible for one of the largest departments of orthopaedic surgery in
the country, providing orthopaedic care at five different hospitals including
Tisch Hospital, the Hospital for Joint Diseases, Bellevue Hospital Center, the
Manhattan Veteran's Administration Medical Center and Jamaica Hospital. He is
also the Director of the Orthopaedic Surgery Residency Program, which trains
more than 60 residents in a five year program.
Dr. Zuckerman holds leadership positions in national organizations and is
President of the American Shoulder and Elbow Surgeons and Chair of the Council
on Education for the American Academy of Orthopaedic Surgeons. He recently
developed and successfully implemented a sponsorship program between the
hospital and the New York Mets. His clinical practice is focused on shoulder
surgery and hip and knee replacement and he is the author or editor of ten
textbooks, 60 chapters and more than 200 articles in the orthopaedic and
scientific literature.
Michael Lax
Director
Michael Lax joined the Board of Directors of the Company in March 2004 and
graduated from the University of Rochester with degrees in Chemical and
Mechanical Engineering. Upon his graduation in 1975, Mr. Lax went to work for
Kodak as a Process and Product Development Engineer. Since 1988, Mr. Lax has
been the President and Chief Executive Officer of Autronic Plastics, Inc. and
its subsidiaries, a plastic manufacturing concern specializing in plastic
product design, mold construction and manufacturing of industrial and precision
components such as medical devices, office products, life safety products and
entertainment packaging. Autronic Plastics, Inc.'s clients include Pfizer,
Borders Books & Music, Blockbuster, Circuit City, Nintendo, and Cooper Lighting
Company. Mr. Lax's 28 years of experience at Autronic Plastics, Inc. have
centered on creative ideation, concept development and managing executions to
ensure that the integrity of the initial designs come alive. Taking the company
in a new direction, Mr. Lax founded Clear-Vu Products in 1990 to further
specialize in the entertainment-packaging sector.
Mr. Lax has been awarded numerous patents for packaging designs, solid state
illumination, and life safety products. In addition, his work and collaborations
have received numerous design awards including a Gold Industrial Design
Excellence Award from the Industrial Designers Society of America.
COMMITTEES OF THE BOARD OF DIRECTORS
Composition of the Board of Directors. Because of the Company's recent
reorganization and implementation of its new business plan, and its ongoing
efforts to engage qualified board members under its new business plan, the
Company does not have a separately designated audit committee or compensation
committee at this time. Accordingly, the Company's Board of Directors has
determined that the Company does not have an audit committee financial expert.
The Company continues to seek new board members in order to implement its
reorganization and new business plan, and appoint a separately designated audit
committee.
SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Section 16(a) of the Securities Exchange Act of 1934 requires the Company's
directors and officers, and persons who own more than 10% of a registered class
of the Company's equity securities, to file initial reports of ownership and
reports of changes in ownership with the Securities and Exchange Commission.
These persons are required by the Securities and Exchange Commission to furnish
the Company with copies of all Section 16(a) reports that they file. Based
solely on the Company's review of these reports and written representations
furnished to the Company, the Company believes that in 2003 each of the
reporting persons complied with these filing requirements, except that a report
on Form 4 reporting one transaction in February 2003 with respect to Mark
Weinreb due on February 8, 2003 was not filed until February 17, 2003, a report
on Form 5 reporting four transactions for the year ended December 31, 2002 with
respect to James J. Fyfe due on February 14, 2003 was not filed until June 10,
2003 and a report on Form 5 reporting four transactions for the year ended
December 31, 2002 with respect to Paul L. Harrison due on February 14, 2003 was
not filed until June 10, 2003. These late filings were inadvertent and required
filings were made promptly after noting the failures to file.
CODE OF ETHICS
The Company has adopted a Code of Ethics that applies to the Company's
principal executive officer, principal financial officer, principal accounting
officer or controller (or persons performing similar functions). A copy of such
Code of Ethics has been filed as Exhibit 14.1 to this Annual Report on Form
10-K.
ITEM 11. EXECUTIVE COMPENSATION
The following table sets forth the aggregate compensation paid during the three
years ended December 31, 2003 to the Company's Chief Executive Officer. No other
executive officer of the Company earned in excess of $100,000 for services
rendered during fiscal 2003.
Summary Compensation Table
Annual Long-Term
Compensation Compensation
------------ ------------
Securities
Underlying All Other
Name and Principal Position Notes Year Salary Options/SAR's Compensation
--------------------------- ----- ---- ------ ------------ ------------
Mark Weinreb (1) 2003 $ 157,154 2,500,000 $ 11,000
Chief Executive Officer
(Appointed February 6, 2003)
Notes:
(1) All other compensation comprises monthly automobile allowances.
OPTION GRANTS IN 2003
The following table provides certain information with respect to options granted
to the Company's chief executive officer during the fiscal year ended December
31, 2003:
Option Grants in Last Fiscal Year
Percent of Potential Realizable Value
Total at Assumed Annual Rates of
Number of Options Exercise Market Stock Price Appreciation
Securities Granted to Price Price on for Option Term(1)
Underlying Employees Date of ---------------------------
Options In per Share Grant Expiration
Name Granted(2) Fiscal Year ($) ($) Date 5% 10%
- ---------------------------------- -------------- ---------- ----------- ------------ ------------- ----------------
Mark Weinreb 2,500,000 100% $0.03 $0.03 2/6/13 $128,275 $204,257
====================
- ----------------------
(1) The Securities and Exchange Commission (the "SEC") requires disclosure of the
potential realizable value or present value of each grant. The 5% and 10%
assumed annual rates of compounded stock price appreciation are mandated by
rules of the SEC and do not represent the Company's estimate or projection of
the Company's future Common Stock prices. The disclosure assumes the options
will be held for the full ten-year term prior to exercise. Such options may be
exercised prior to the end of such ten-year term. The actual value, if any, an
executive officer may realize will depend on the excess of the stock price over
the exercise price on the date the option is exercised. There can be no
assurance that the stock price will appreciate at the rates shown in the table.
(2) These options vested immediately.
OPTION EXERCISES AND HOLDINGS
The following table provides information concerning options exercised during
2003 and the value of unexercised options held by each of the executive officers
named in the Summary Compensation Table at December 31, 2003.
Option Values at December 31, 2003
Number of
Securities Underlying
Shares Unexercised Options Value of
Acquired at December 31, 2003 In-the-Money Options at
On (# of shares) December 31, 2003 ($)(1)
Exercise Value --------------------------------- -------------------------------------
Name (# shares) Realized Exercisable Unexercisable Exercisable Unexercisable
--------------------- ------------- ------------- -------------- ------------------ ------------------- -----------------
Mark Weinreb -- -- 2,500,000 -- $300,000 --
==========================================================================================================================
---------------------
(1) Based on $0.15 per share, the closing price of the Company's Common Stock, as reported by the
OTC Bulletin Board, on December 31, 2003.
EMPLOYMENT AGREEMENTS
On February 6, 2003, Mr. Weinreb was appointed President and Chief Executive
Officer of the Company and the Company entered into an employment agreement with
Mr. Weinreb. The employment agreement has an initial term of three years, with
automatic annual extensions unless terminated by the Company or Mr. Weinreb at
least 90 days prior to an applicable anniversary date. The Company has agreed to
pay Mr. Weinreb an annual salary of $180,000 for the initial year of the term,
$198,000 for the second year of the term, and $217,800 for the third year of the
term. In addition, he is entitled to an annual bonus in the amount of $20,000
for the initial year in the event, and concurrently on the date, that the
Company has received debt and/or equity financing in the aggregate amount of at
least $1,000,000 since the beginning of his service, and $20,000 for each
subsequent year of the term, without condition.
In addition, the Company, pursuant to its newly adopted 2003 Equity
Participation Plan, entered into a Stock Option Agreement with Mr. Weinreb (the
"Initial Option Agreement"). Under the Initial Option Agreement, the Company
granted Mr. Weinreb the right and option, exercisable for 10 years, to purchase
up to 2,500,000 shares of the Company's Common Stock at an exercise price of
$0.03 per share and otherwise upon the terms set forth in the Initial Option
Agreement. In addition, in the event that the closing price of the Company's
Common Stock equals or exceeds $0.50 per share for any five consecutive trading
days during the term of the employment agreement (whether during the initial
term or an annual extension), the Company has agreed to grant to Mr. Weinreb, on
the day immediately following the end of the five day period, an option for the
purchase of an additional 2,500,000 shares of the Company's Common Stock for an
exercise price of $0.50 per share, pursuant to the 2003 Equity Participation
Plan and a Stock Option Agreement to be entered into between the Company and Mr.
Weinreb containing substantially the same terms as the Initial Option Agreement,
except for the exercise price and that the option would be treated as an
"incentive stock option" for tax purposes only to the maximum extent permitted
by law (the "Additional Option Agreement"). The Company has agreed to promptly
file with the Securities and Exchange Commission a Registration Statement on
Form S-8 (the "Registration Statement") pursuant to which the issuance of the
shares covered by the 2003 Equity Participation Plan, as well as the resale of
the Common Stock issuable upon exercise of the Initial Option Agreement, are
registered. Additionally, the Company has agreed, following any grant under the
Additional Option Agreement, to promptly file a post-effective amendment to the
Registration Statement pursuant to which the Common Stock issuable upon exercise
thereof shall be registered for resale. Mr. Weinreb has agreed that he will not
resell publicly any shares of the Company's Common Stock obtained upon exercise
of any Initial Agreement or the Additional Option Agreement prior to the first
anniversary of the date of the employment agreement.
In connection with the hiring of Mr. Weinreb and in anticipation of its new
business line, on July 24, 2003, the Company held a meeting of stockholders to
elect two directors, to approve and ratify the Company's 2003 Equity
Participation Plan pursuant to which 15,000,000 shares of the Company's Common
Stock are authorized to be issued, approve an amendment to the Company's
Certificate of Incorporation to increase the authorized number of shares of
Common Stock to 250,000,000, and approve a change of the Company's name to
"Phase III Medical, Inc."
Director Compensation
All current independent directors have individually received options to purchase
300,000 shares of the Company's Common Stock pursuant to the Company's 2003
Equity Participation Plan at prices ranging from $0.05 to $0.15. In addition to
these options, all independent directors are reimbursed for out of pocket travel
expenses and will receive an annual option grant to purchase 50,000 shares of
the Company's Common Stock on the date of the Company's annual stockholder's
meeting; provided; however, that no director may receive more than one grant of
these options in any calendar year. Upon achieving certain target increases in
stock price for a defined period of time during an existing independent
directors tenure, the Company has agreed to grant each director an additional
option to purchase 100,000 shares of the Company's Common Stock substantially
upon the same terms of the options to purchase 300,000 shares of the Company's
Common Stock previously granted, except for the exercise price of such options.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT
The following table sets forth information as to the number of shares of the
Company's Common Stock beneficially owned, as of March 8, 2004, by (i) each
beneficial owner of more than five percent of the outstanding Common Stock, (ii)
each current named executive officer and director and (iii) all current
executive officers and directors of the Company as a group. All shares are owned
both beneficially and of record unless otherwise indicated. Unless otherwise
indicated, the address of each beneficial owner is c/o Phase III Medical, Inc.,
330 South Service Road, Suite 120, Melville, New York 11747.
Number and Percentage of Shares of Common Stock Owned
Percentage
# of Shares of Common Stock
Name and Address of Beneficial Notes Beneficially Beneficially Owned
Owner Owned (See Note 1)
Joel San Antonio
56 North Stanwich Road
Greenwich, CT 06831 3,752,500 13.9%
Mark Weinreb (2) 2,540,000 9.4%
Wayne Marasco (3) 800,000 3.0%
Michael Lax (3) 300,000 1.1%
Joseph Zuckerman, M.D. (3) 550,000 2.0%
All current directors and officers as a
group (four persons) (2) (3) 4,190,000 15.6%
Notes:
(1) Based on 26,926,460 shares of Common Stock outstanding on March 8, 2004.
(2) Includes 2,500,000 currently exercisable options to purchase Common Stock.
(3) Includes 300,000 currently exercisable options to purchase Common Stock.
EQUITY COMPENSATION PLAN INFORMATION
The following table gives information about the Company's Common Stock that may
be issued upon the exercise of options, warrants and rights under the Company's
2003 Equity Participation Plan as of December 31, 2003. This plan was the
Company's only equity compensation plan in existence as of December 31, 2003
(c)
Number of Securities
Remaining Available
For Future Issuance
(a) (b) Under Equity
Number of Securities to Weighted-Average Compensation Plan
be Issued Upon Exercise Exercise Price of (Excluding Securities
of Outstanding Options, Outstanding Options, Reflected In
Plan Category Warrants and Rights Warrants and Rights Column(a))
------------- ------------------------- --------------------- ------------------------
Equity Compensation Plans
Approved by
Shareholders............ 3,700,000 $0.05 11,300,000
Equity Compensation
Plans Not Approved by
Shareholders 0 0 0
------------------------- --------------------- ------------------------
TOTAL 3,700,000 $0.05 11,300,000
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
Not applicable.
ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES
All audit and audit-related work and all non-audit work performed by the
Company's independent accountants is approved in advance by the Board of
Directors of the Company, including the proposed fees for such work. The Audit
Committee is informed of each service actually rendered.
Audit Fees. Audit fees billed or expected to be billed to the Company by the
Company's principal accountant for the audit of the financial statements
included in the Company's Annual Reports on Form 10-K, and reviews of the
financial statements included in the Company's Quarterly Reports on Form 10-Q,
for the years ended December 31, 2003 and 2002 totaled approximately $48,185 and
$48,228, respectively.
Audit-Related Fees. The Company was billed $0 and $0 by the Company's principal
accountant for the fiscal years ended December 31, 2003 and 2002, respectively,
for assurance and related services that are reasonably related to the
performance of the audit or review of the Company's financial statements and are
not reported under the caption Audit Fees above.
Tax Fees. The Company was billed or expected to be billed an aggregate of $5,072
and $2,900 by the Company's principal accountant for the fiscal years ended
December 31, 2003 and 2002, respectively, for tax services, principally advice
regarding the preparation of income tax returns.
All Other Fees. The Company incurred fees for the fiscal years ended December
31, 2003 and 2002, respectively, for permitted non-audit services of $3,230 and
$0, respectively.
The Company's Board of Directors pre-approved the Company's engagement of Holtz
Rubenstein & Co., LLP to act as the Company's independent auditor for the fiscal
year ended December 31, 2003. The Company's Board of Directors pre-approved
Travis Wolff & Company, L.L.P. to act as the Company's independent auditor for
the fiscal years ended December 31, 2002 and December 31, 2001. The Company's
independent auditors performed all work only with its full time permanent
employees.
PART IV
ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON
FORM 8-K
The following documents are being filed as part of this Report:
(a)(1) Financial Statements:
Reference is made to the Index to Financial Statements and Financial Statement
Schedule on Page F-1.
(a)(2) Financial Statement Schedule.
Reference is made to the Index to Financial Statements and Financial Statement
Schedule on Page F-1.
All other schedules have been omitted because the required information is not
present or is not present in amounts sufficient to require submission of the
schedule, or because the information required is included in the Financial
Statements or Notes thereto.
(a)(3) Exhibits:
3 (a) Certificate of Incorporation filed September 18, 1980 (1) 3
(b) Amendment to Certificate of Incorporation filed September 29, 1980 (1) 3
(c) Amendment to Certificate of Incorporation filed July 28, 1983 (2) 3(b)
(d) Amendment to Certificate of Incorporation filed February 10, 1984 (2) 3(d)
(e) Amendment to Certificate of Incorporation filed March 31, 1986 (3) 3(e)
(f) Amendment to Certificate of Incorporation filed March 23, 1987 (4) 3(g)
(g) Amendment to Certificate of Incorporation filed June 12, 1990 (5) 3.8
(h) Amendment to Certificate of Incorporation filed September 27, 1991 (6) 3.9
(i) Certificate of Designation filed November 12, 1994 (7) 3.8
(j) Amendment to Certificate of Incorporation filed September 28, 1995 (9) 3(j)
(k) Certificate of Designation for the Series B Preferred Stock
dated May 18, 1998 (10) C 3(f)
(l) Amendment to Certificate of Incorporation dated May 18, 1998 (10) A
(m) Amendment to Certificate of Incorporation filed July 24, 2003 (15) 3.1
(n) By-laws of the Corporation, as amended on April 25, 1991 (6)
4 (a) Form of Underwriter's Warrant (6) 4.9.1
(b) Form of Promissory Note - 1996 Offering (9) 4(b)
(c) Form of Promissory Note - 1997 Offering (9) 4(c)
(d) Form of Common Stock Purchase Warrant - 1996 Offering (9) 4(d)
(e) Form of Common Stock Purchase Warrant - 1997 Offering (9) 4(e)
(f) Form of Promissory Note - September 2002 Offering (13) 4.1
(g) Form of Promissory Note - February 2003 Offering (13) 4.2
(h) Form of Promissory Note - March 2003 Offering (13) 4.3
10 (a) 1992 Stock Option Plan (8) B
(b) Stock Purchase Agreement, dated as of March 4, 1998, between
the Company and the Initial Purchasers named therein (10) B
(c) 1998 Employee Stock Option Plan (10) D
(d) Stock Contribution Exchange Agreement with StrandTek International, Inc.
dated January 7, 2002, as amended on February 11, 2002 (11) 10(o)
(e) Supplemental Disclosure Agreement to Stock Contribution Exchange
Agreement with StrandTek International, Inc. dated January 7, 2002 (11) 10(p)
(f) Employment Agreement dated as of February 6, 2003 by and between
Corniche Group Incorporated and Mark Weinreb (12) 99.2
(g) Stock Option Agreement dated as of February 6, 2003 between
Corniche Group Incorporated and Mark Weinreb (12) 99.3
(h) Corniche Group Incorporated 2003 Equity Participation Plan (12) 99.4
(i) Royalty Agreement, dated as of December 5, 2003, by and between
Parallel Solutions, Inc. and Phase III Medical, Inc. (13)(14) 10.1
(j) Form of Stock Option Agreement (13) 10.2
14 (a) Code of Ethics for Senior Financial Officers (13) 14.1
23 (a) Consent of Holtz Rubenstein & Co., LLP (13) 23.1
31 (a) Certification of Chief Executive Officer pursuant to Section 302
of the Sarbanes-Oxley Act of 2002 (13) 31.1
32 (a) Certification pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (13) 32.1
Notes:
(1) Filed with the Securities and Exchange Commission as an exhibit,
numbered as indicated above, to the Company's registration statement on
Form S-18, File No. 2-69627, which exhibit is incorporated here by
reference.
(2) Filed with the Securities and Exchange Commission as an exhibit,
numbered as indicated above, to the Company's registration statement on
Form S-2, File No. 2-88712, which exhibit is incorporated here by
reference.
(3) Filed with the Securities and Exchange Commission as an exhibit,
numbered as indicated above, to the Company's registration statement on
Form S-2, File No. 33-4458, which exhibit is incorporated here by
reference.
(4) Filed with the Securities and Exchange Commission as an exhibit,
numbered as indicated above, to the Company's annual report on Form
10-K for the year ended September 30, 1987, which exhibit is
incorporated here by reference.
(5) Filed with the Securities and Exchange Commission as an exhibit,
numbered as indicated above, to the Company's registration statement on
Form S-3, File No. 33-42154, which exhibit is incorporated here by
reference.
(6) Filed with the Securities and Exchange Commission as an exhibit to the
Company's registration statement on Form S-1, File No. 33-42154, which
exhibit is incorporated here by reference.
(7) Filed with the Securities and Exchange Commission as an exhibit,
numbered as indicated above, to the Company's annual report on Form
10-K for the year ended September 30, 1994, which exhibit is
incorporated here by reference.
(8) Filed with the Securities and Exchange Commission as an exhibit, as
indicated above, to the Company's proxy statement dated March 30, 1992,
which exhibit is incorporated here by reference.
(9) Filed with the Securities and Exchange Commission as an exhibit,
numbered as indicated above, to the Company's annual report on Form
10-K for the year ended March 31, 1996, which exhibit is incorporated
here by reference.
(10) Filed with the Securities and Exchange Commission as an exhibit, as
indicated above, to the Company's proxy statement dated April 23, 1998,
which exhibit is incorporated here by reference.
(11) Filed with the Securities and Exchange Commission as an exhibit,
numbered as indicated above, to the Company's annual report on Form
10-K for the year ended December 31, 2001, which exhibit is
incorporated here by reference.
(12) Filed with the Securities and Exchange Commission as an exhibit,
numbered as indicated above, to the current report of the Company on
Form 8-K, dated February 6, 2003, which exhibit is incorporated here by
reference.
(13) Filed herewith.
(14) Certain portions of this exhibit have been omitted based upon a request
for confidential treatment. The omitted portions of this exhibit have
been filed separately with the Securities and Exchange Commission on a
confidential basis.
(15) Filed with the Securities and Exchange Commission as an exhibit,
numbered as indicated above, to the current report of the Company on
Form 8-K, dated July 24, 2003, which exhibit is incorporated here by
reference.
(b) Reports on Form 8-K
On December 12, 2003, the Company filed a Current Report on Form 8-K (under
Items 5 and 7) regarding the Royalty Agreement, dated as of December 5, 2003, by
and between Parallel Solutions, Inc. and Phase III Medical, Inc.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Company has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
Phase III Medical, Inc.
By: /s/ Mark Weinreb
----------------
Mark Weinreb, President
Dated: March 30, 2004.
Pursuant to the requirements of the Securities Exchange Act of 1934,
this report has been signed below by the following persons on behalf of the
Company and in the capacities and on the dates indicated:
Signatures Title Date
- ---------- ----- ----
/s/ Mark Weinreb Director, President
- ------------------------------ and Chief Executive Officer March 30, 2004
Mark Weinreb
/s/ Wayne Marasco Director March 30, 2004
- ------------------------------
Wayne Marasco
/s/ Joseph Zuckerman Director March 30, 2004
- ------------------------------
Joseph Zuckerman
/s/ Michael Lax Director March 30, 2004
- ------------------------------
Michael Lax
PHASE III MEDICAL, INC.
Table of Contents
Page
----------------------
Report of Independent Certified Public Accountants -
Holtz Rubenstein & Co., LLP F - 1
Report of Independent Certified Public Accountants -
Travis, Wolff & Company, L.L.P. F - 2
Financial Statements:
Consolidated Balance Sheets at December 31, 2003 and 2002 F - 3
Consolidated Statements of Operations
Years Ended December 31, 2003, 2002 and 2001 F - 4
Consolidated Statements of Stockholder's Equity (Deficit)
Years Ended December 31, 2003, 2002 and 2001 F - 5
Consolidated Statements of Cash Flows
Years Ended December 31, 2003, 2002 and 2001 F - 6
Notes to Consolidated Financial Statements F - 8 - F - 21
Independent Auditors' Report
Board of Directors and Stockholders
Phase III Medical, Inc.
Melville, New York
We have audited the accompanying consolidated balance sheet of Phase III
Medical, Inc. as of December 31, 2003 and the related consolidated statements of
operations, stockholders' equity (deficit ) and cash flows for the year then
ended. These consolidated financial statements are the responsibility of the
Company's management. Our responsibility is to express an opinion on these
consolidated financial statements based on our audit
We conducted our audit in accordance with auditing standards generally accepted
in the United States of America. Those standards require that we plan and
perform the audit to obtain reasonable assurance about whether the consolidated
financial statements are free of material misstatement. An audit includes
examining, on a test basis, evidence supporting the amounts and disclosures in
the consolidated financial statements. An audit also includes assessing the
accounting principles used and significant estimates made by management, as well
as evaluating the overall consolidated financial statement presentation. We
believe that our audit provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present
fairly, in all material respects, the financial position of Phase III Medical,
Inc. as of December 31, 2003 and the results of their operations and their cash
flows for the year then ended in conformity with accounting principles generally
accepted in the United States of America.
The accompanying consolidated financial statements have been prepared assuming
that the Company will continue as a going concern. As discussed in Note 1 to the
consolidated financial statements, the Company's recurring losses from
operations raise substantial doubt about its ability to continue as a going
concern. Management's plans in regard to these matters are also described in
Note 1. The consolidated financial statements do not include any adjustments
that might result from the outcome of this uncertainty.
/s/ HOLTZ RUBENSTEIN & CO., LLP
Melville, New York
February 3, 2004
F-1
REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS
To the Board of Directors of
Phase III Medical, Inc.
We have audited the accompanying consolidated balance sheet of Phase III
Medical, Inc. (the "Company") as of December 31, 2002 and the related
consolidated statements of operations, stockholders' equity, and cash flows for
the years ended December 31, 2002 and 2001. These consolidated financial
statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these consolidated financial
statements based on our audits.
We conducted our audits in accordance with auditing standards generally accepted
in the United States of America. Those standards require that we plan and
perform the audit to obtain reasonable assurance about whether the consolidated
financial statements are free of material misstatement. An audit includes
examining, on a test basis, evidence supporting the amounts and disclosures in
the consolidated financial statements. An audit also includes assessing the
accounting principles used and significant estimates made by management, as well
as evaluating the overall consolidated financial statement presentation. We
believe that our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present
fairly, in all material respects, the consolidated financial position of Phase
III Medical, Inc. as of December 31, 2002 and the consolidated results of their
operations and their cash flows for the years ended December 31, 2002 and 2001,
in conformity with accounting principles generally accepted in the United States
of America.
The accompanying consolidated financial statements have been prepared assuming
Phase III Medical, Inc. will continue as a going concern. As discussed in the
accompanying notes to the consolidated financial statements, the Company sold
its insurance subsidiary in July 2001. Additionally, the Company discontinued
sales of its extended warranty service contracts through its website in December
2001. Accordingly, the Company has no operations nor available means to finance
its current expenses and with which to pay its current liabilities. These
factors raise substantial doubt about the Company's ability to continue as a
going concern. Management's plans in regard to these matters are described in
Note 13. The consolidated financial statements do not include any adjustments
that might result from the outcome of this uncertainty.
/s/TRAVIS, WOLFF & COMPANY, L.L.P.
Dallas, Texas
March 11, 2003
F-2
PHASE III MEDICAL, INC.
Consolidated Balance Sheets
December 31,
-------------------------
2003 2002
------------ -----------
ASSETS
Current assets:
Cash and cash equivalents $ 210,947 $ 19,255
Notes receivable, net of allowance of $250,000 in 2002 - 1,000,000
Prepaid expenses and other current assets, net of allowance
of $8,103 in 2002 18,024 40,094
------------ -----------
Total current assets 228,971 1,059,349
Property and equipment, net 1,935 -
Deferred acquisition costs 77,782 123,835
Other assets 3,000 -
------------ -----------
$ 311,688 $ 1,183,184
============ ===========
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current liabilities:
Interest and dividends payable - preferred stock $ 433,196 $ 385,512
Accounts payable 87,896 344,279
Accrued liabilities